• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Consonance Capital Partners Completes Recapitalization of Orsini Pharmaceutical Services in Partnership with Management Team

Share:

February 11, 2019

Consonance Capital Partners, a leading healthcare-focused private equity fund, announced today that it completed the recapitalization of Orsini Pharmaceutical Services, LLC, in partnership with the Companys CEO and President, Michael Fieri. Orsini is a leading rare disease specialty pharmacy differentiated by its personalized service and focus on complex conditions that require a high-touch patient journey. Financial terms of the transaction were not disclosed.

Orsinis mission is to improve the quality of life for patients living with difficult conditions, commented Michael Fieri. We partnered with Consonance not only because of their similar commitment to improving patient care but also as a result of their sector knowledge, extensive relationships, national reach, and their decades of healthcare investing experience more broadly. I am confident the additional resources this partnership brings will help us further expand our services and support our growth.

Consonance has long viewed specialty pharmacy as a sector uniquely positioned to improve outcomes through increased adherence and high-touch care coordination, noted Stephen McKenna, Managing Partner & Co-Founder of Consonance Capital Partners. Orsini is an exemplary model of how an innovative patient-centric approach and consistent culture of care can improve quality and lead to a strong value proposition for patients, manufacturers, and payors. We are excited to partner with Mike Fieri and the team to further expand their proven model of patient care targeting those who need it most.

Javier Starkand, a Principal of Consonance Capital Partners, added, At Consonance, we pride ourselves on investing in companies that improve lives and patient care, which is the reason we are excited to join Mike and the rest of the Orsini team. We have been thoroughly impressed with Orsinis highly personalized approach to care and its reputation for innovation, data collection capabilities, and domain expertise in rare diseases, and we look forward to working with them as they continue to improve care for patients.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Consonance Capital Partners was advised by Latham & Watkins LLP and Bass, Berry & Sims PLC. Orsini Pharmaceutical Services was advised by Barone Law Group P.C., Levenfeld Pearlstein, LLC, and Brown & Fortunato, P.C.

Date: February 11, 2019

Source: Global Banking & Finance Review

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • German Startup Inveox Secures €17m, Axial3D Raises Funds to Accelerate US Expansion, and More News BriefsGerman Startup Inveox Secures €17m, Axial3D Raises Funds to Accelerate US Expansion, and More News Briefs
  • Zócalo Health Raises $5M to Launch Primary Care Services for LatinosZócalo Health Raises $5M to Launch Primary Care Services for Latinos
  • HeartVista Raises $8.65M to Expand One Click, AI-Guided MRI PlatformHeartVista Raises $8.65M to Expand One Click, AI-Guided MRI Platform
  • Trust in health sector takes a hit in major markets, Edelman research findsTrust in health sector takes a hit in major markets, Edelman research finds
  • GTCR-Backed Resonetics Acquires Caribou TechnologiesGTCR-Backed Resonetics Acquires Caribou Technologies
  • Paraneoplastic Neurologic Syndrome Market Size, Revenue Analysis, Industry Outlook, Forecast, 2022-2029 | Sun Pharmaceutical Industries Ltd., Abbott, Teva Pharmaceutical Industries Ltd., Bausch Health Companies IncParaneoplastic Neurologic Syndrome Market Size, Revenue Analysis, Industry Outlook, Forecast, 2022-2029 | Sun Pharmaceutical Industries Ltd., Abbott, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc
  • Pharmaceutical Processing Seals Global Market to Reach $2.79 Billion By 2026Pharmaceutical Processing Seals Global Market to Reach $2.79 Billion By 2026
  • Ultromics Scores $10M for Its Cardiac Decision Support ToolUltromics Scores $10M for Its Cardiac Decision Support Tool

Trending This Week

  • Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
  • GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies GroupGelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security Market
  • Life Launches AI Clinical Trial Matching Assistant for Cancer
  • 79% of Healthcare Execs Believe Most Drug Diversion Goes Undetected
  • Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine
  • FDA Releases Updated Final Guidance for its Breakthrough Devices Program

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications